LUND, Sweden – Immunovia (publ.), the pancreatic cancer diagnostics company, will publish its second quarter 2025 results on August 28, 2025, at 8:30 am CEST. Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CEST. The report, together with the presentation slides, will be available at www.immunovia.com.

Jeff Borcherding, CEO will present Immunovia’s development ahead of the upcoming launch of the PancreaSure test. The presentation will be held in English and be followed by a Q&A session.

You are welcome to join via webcast or phone, see details below. Please dial in a few minutes before the presentation starts.

Telephone numbers and webcast
Sweden: +46 (0)8 5051 0031

United Kingdom: +44 (0) 207 107 06 13

United States: +1 631 570 5613

Link to webcast
https://creo-live.creomediamanager.com/10102133-d8c1-4182-b5cb-a057350c1040

For further information, please contact
Jeff Borcherding, CEO
jeff.borcherding@immunovia.com

Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world’s largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm.
For more information, please visit www.immunovia.com.

Attachments
INVITATION TO IMMUNOVIA’S Q2 PRESENTATION

Läs mer på MFN